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Background: Grass allergen immunotherapy (AIT) reduces symptom severity in seasonal allergic rhinoconjunctivitis
(ARC) but its impact on general health-related utility has not been characterised for the purposes of economic
evaluation. The aim of this study was to model the preferred measure of utility, EQ-5D index, from symptom
severity and estimate incremental quality adjusted life years (QALYs) associated with SQ-standardised grass
immunotherapy tablet (GRAZAX®, 75,000 SQ-T/2,800 BAU, ALK, Denmark).
Methods: Data were analysed from five consecutive pollen seasons in a randomised placebo controlled trial of
GRAZAX®. Binomial and Gaussian mixed effects modelling related weekly EQ-5D index score to daily symptom and
medication scores (DSS & DMS respectively). In turn, daily EQ-5D index was estimated from ARC symptoms and
medication use.
Results: DSS and DMS were the principal predictors of ‘perfect’ health (EQ-5D = 1.000; binomial) and ‘imperfect’ health
(EQ-5D < 1.000; Gaussian). Each unit increase in DSS and DMS reduced the odds of ‘perfect’ health (EQ-5D = 1.000) by
27% and 16% respectively, and reduced ‘imperfect’ health by 0.17 and 0.13, respectively. Gender remained the only
other significant main fixed effect (Male odds ratio [OR] = 1.82). Incremental estimated EQ-5D index utility for GRAZAX®
was observed from day -30 to day +70 of the pooled pollen season; mean daily utility for GRAZAX® = 0.938 units (95%
CI 0.932-0.943) vs. 0.914 (0.907-0.921) for placebo, an incremental difference of 0.0238 (p < 0.001). This translates into an
incremental 0.0324 Quality Adjusted Life Years over the five year study period.
Conclusions: ARC symptoms and medication use are the main predictors of EQ-5D index. The incremental QALYs ob-
served for GRAZAX® may not fully describe the health benefits of this treatment, suggesting that economic modelling
may be conservative.Background
The increasing prevalence of atopic disease is a significant
global health concern with up to 20% of Western adults
suffering from allergic rhinoconjunctivitis (ARC) [1-3].
Although direct health care costs may be relatively modest
compared to some other chronic disease (on average £49
per person per annum in the UK [4] after adjustment for
inflation [5]), indirect costs such as work and school
absenteeism and reduced workplace productivity are* Correspondence: currie@cardiff.ac.uk
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unless otherwise stated.recognised to be considerable. For instance, it has been
estimated that 3.5 million working days are lost annu-
ally in the United States due to this condition [6], and
in Sweden the total annual cost of lost productivity is
€20082.7 billion [7].
Specific allergen immunotherapy potentially offers not-
able benefits over conventional symptomatic manage-
ment, most notably clinical tolerance to allergen exposure
sustained beyond the initial period of treatment [8]. Fol-
lowing extensive demonstration of both efficacy and toler-
ability [9-15], the SQ-standardized, containing Phleum
pratense (timothy grass) pollen extract (GRAZAX® 75,000
SQ-T/2,800 BAU, ALK, Denmark)) is approved in Europetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rhinoconjunctivitis in adults and children.
Economic evaluation of health technologies is an integral
part of the post-approval reimbursement process. Most
favoured methods of comparison involve evaluation of
value for money in the form of cost-utility analyses (CUA)
which measures health in terms of quality-adjusted life
years (QALYs). QALYs quantify patients’ health-related
utility on a scale from 0 (dead) to 1 (perfect health) allow-
ing the health consequence of any clinical condition to
be compared [16]. The most widely accepted method for
determining QALYs is the EuroQoL-5D (EQ-5D) instru-
ment [17]. The EQ-5D describes the patients’ health state
using five dimensions: 1. Mobility, 2. Self-care, 3. Usual
activities, 4. Pain/Discomfort and 5. Anxiety/Depression.
Each of these dimensions has a number of potential re-
sponses. These are then transformed into a single index by
applying a formula that attaches weights to each of the re-
sponse levels in each dimension [18]. The weighting for-
mulae are based on the valuation of EQ-5D health states
from general population samples, and reflect the health
preferences of their country of origin [19].
Rhinoconjunctivitis symptoms can vary rapidly in af-
fected individuals in tandem with daily variation in pollen
counts during the spring and summer months. When com-
pleting the EQ-5D, respondents are instructed to “indicate
which statements best describe [their] own health state
today” [17]. However clinical ARC studies (including those
for GRAZAX) never record daily EQ-5D observations.
The purpose of this study was explore whether a model
of daily health-related utility using EQ-5D derived data
from randomised trials would more accurately reflect
quality of life variation than weekly observations, and to
use these data to determine the long-term utility benefit
of GRAZAX® versus placebo in combination with the
symptom relieving drugs taken normally by sufferers.
Methods
Study subjects
Details of the randomized, parallel group, double-blind,
placebo-controlled phase-3 trial conducted according to the
Declaration of Helsinki at 43 centers in 7 countries, asses-
sing the efficacy and safety of grass allergen immunotherapy
tablet 75,000 SQ-T (GRAZAX®; 75,000 SQ-T/2,800 BAU,
ALK, Denmark) in subjects with seasonal grass pollen-
induced rhinoconjunctivitis have been published previously
(ClinicalTrials.gov number: NCT00227279) [11,13,20].
The study was conducted from 2005 to 2009, across 51
sites in 8 European countries (Austria, Denmark, Germany,
Italy, The Netherlands, Spain, Sweden, and the United
Kingdom). A total of 634 participants were randomised
to either receive once-daily GRAZAX® or a placebo tablet
similar in taste, smell and appearance. Double-blind treat-
ment started at least 16 weeks before the planned start ofthe grass pollen season and continued throughout the
pollen season. The start of each grass pollen season was
defined as the first day of three consecutive days with
grass pollen count of 10 grains/m3 or more with the
end of the season defined as the last day in the last oc-
currence of three consecutive days with pollen count of
more than 10 grains/m3. Patients were treated for three
years and were followed for a further two years post
treatment completion.
Main inclusion criteria were as follows: age 18 to
65 years; a clinical history of moderate-to-severe grass
pollen-induced allergic rhinoconjunctivitis of two years or
more requiring treatment during the grass pollen season;
positive skin prick test result (wheal diameter ≥3 mm) and
serum specific IgE (IgE CAP class ≥2) to Phleum p. Main
exclusion criteria were as follows: forced expiration vol-
ume (FEV1) less than 70% of the predicted value; a clinical
history of symptomatic seasonal allergic rhinitis/asthma
due to tree or weed pollen potentially overlapping the
grass pollen season; a clinical history of significant active
perennial allergic rhinitis/asthma caused by an allergen to
which the participant was regularly exposed; previous im-
munotherapy within the last five years; a history of ana-
phylaxis or angioedema; and pregnancy.
Rhinoconjunctivitis symptom and medication scores
Each day for the full five years of the trial using an elec-
tronic diary, six rhinoconjunctivitis symptoms were mea-
sured on a scale from 0 to 3, with the following values: no
symptoms (score = 0), mild symptoms (score = 1), moder-
ate symptoms (score = 2), or severe symptoms (score = 3).
The symptoms scored were: runny nose, blocked nose,
sneezing, itchy nose, gritty feeling/red/itchy eyes, and
watery eyes. The total daily rhinoconjunctivitis symptom
score (DSS) was calculated for each participant as the sum
of all individual symptom scores. The maximal total daily
rhinoconjunctivitis symptom score was 18 arbitrary units.
DSS was treated as a pseudo-continuous variable.
Symptom relieving medications used for the treatment
of rhinoconjunctivitis were administered to all partici-
pants during the grass pollen seasons of the trial. The
medications were to be used as required and entered in
the diary by the subject. Each medication was scored ac-
cording to symptom control (from 1 to 6 arbitrary units)
as follows: desloratadine, 5 mg, up to 1 tablet daily (up
to 6 points per day); olopatadine eye drops, 1.0 mg/mL,
up to 1 drop per eye twice daily (up to 6 points per day);
budesonide nasal spray, 32 mg per puff, up to 2 puffs
per nostril twice daily (up to 8 points per day); and pred-
nisone, 5 mg per tablet, up to 10 tablets per day (up to
16 points per day). The maximum daily medication
score (DMS) was 36; however, if the recommended dose
was exceeded, the actual score was used [20]. DMS was
also treated as a pseudo-continuous variable.
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With regard to this specific analysis and not the pivotal
trial, the primary endpoint was the EQ-5D index, calcu-
lated from weekly EQ-5D survey responses. In this
multinational study there was a requirement to express
utility by a single value set as (mixing value sets from
each respective study would have made interpretation
impossible) therefore we followed the advice of the
EuroQoL group that “In the absence of a suitable candi-
date, adopt the most robust valuation set (the UK TTO
set).” [18,19].
Model derivation and development
Subjects in the study cohort were primarily younger
adults ― average age was 34 years ― with low co-
morbidity, aside from a history of seasonal allergic con-
junctivitis. Therefore it was expected that a high propor-
tion of the EQ-5D responses would indicate a ‘perfect’
health state (‘11111’ or 1.000 unit), creating a highly
skewed distribution. For this reason EQ-5D index values
were analysed using a ‘two-part’, mixed modelling ap-
proach. In the first stage, the response variable (EQ-5D
index) was modelled as a binary variable indicating ‘per-
fect health’ (1.000) or ‘imperfect health’ (<1.000). Re-
sponses indicating ‘imperfect health’ were then evaluated
in a second stage of modelling where the EQ-5D index
was used as a pseudo-continuous variable. Two-part
modelling has been shown to be less biased than other
limited dependent variable regression models for dealing
with the bounded nature of health utility data including
censored Tobit and censored least absolute deviation
(CLAD) regression methods [21-23]. Selection of predic-
tors, both fixed and random effects, for inclusion in the
models was informed using backward stepwise selection
methods where covariates below the specified significance
level (p < 0.05/t < 2) were identified and removed.
Binomial modelling of ‘perfect’ health
In the first stage of the modelling process, the relation-
ship between the EQ-5D index (as a binary response
variable) with observed predictor variables was deter-
mined using a mixed effects logistic model. Gender, age,
treatment arm, diagnosis of asthma, daily rhinoconjunc-
tivitis symptom score, daily medication score, a com-
bined symptom/medication score, and the number of
days with severe symptoms were considered as fixed ef-
fects. Year of treatment and study country were consid-
ered as random effects to adjust for variation due to
differences between years and countries.
To identify subjects for entry into the next modelling
stage, a threshold was calculated for use with the probabil-
ity of ‘perfect health’ predicted by the logistic model. Using
the predicted probabilities from the logistic model, a classi-
fication threshold (or cut-off) was calculated. This wasobtained by considering all possible thresholds (0.001 –
0.999) and selecting the threshold that yielded the max-
imum combined specificity and sensitivity. In the absence
of domain information to indicate that being in perfect
health and identified as being in perfect health, is of differ-
ent importance to not being in perfect and identified as
not being in perfect health we gave, specificity and sensitiv-
ity equal weighting in calculation of the threshold. All ob-
servations with a predicted probability of ‘perfect health’
above the threshold were assigned a predicted EQ-5D
index score of 1.000; those below the threshold were iden-
tified for inclusion in the second modelling stage.Continuous modelling of those with imperfect health
In the second stage of the modelling process, the rela-
tionship of the EQ-5D index (as a pseudo-continuous re-
sponse variable) with observed predictor variables was
determined using a generalized linear, mixed model. The
dependent variable, pseudo-continuous EQ-5D index
was transformed using a cubic function to achieve nor-
mally distributed residuals. The same candidate predic-
tors as in the first (binomial) stage model were also
considered for fixed and random effects.
Empirically we reasoned that an individual’s EQ-5D re-
sponse to the fixed-effects acting upon them would be
consistent and therefore the error terms within a subject
were correlated. We further assumed an autoregressive
process would operate under the premise that past values
have an effect on current values. We considered that a
first order process (AR (1)), meaning that the current
value is based on the immediately preceding value, would
adequately represent this implied relationship. Residuals
were assumed to be normally distributed and the explana-
tory power of predictors as fixed or random effects were
compared using Akaike’s Information Criterion (AIC)
where appropriate. All analyses were carried out in R (ver-
sion 2.14.0) [24].Comparison of utility
The two-part model and probability threshold developed
using the weekly diary data were then retrospectively ap-
plied to the daily diary data in order to calculate the in-
dividual QALYs for the study period. Due to the annual
variations in pollen season intensity observed during the
trial [20], a final pooled five-year estimate of incremental
QALYs between the treatment arms was made by calcu-
lating mean simulated EQ-5D index for each pollen day
relative to the designated start of each respective pollen
season, defined as the first day of three consecutive days
with grass pollen count of 10 grains/m3 or more [12].
To account for any observable treatment effect outside
the study-defined pollen season, a pooled estimate of in-
cremental QALYs was made from the first day where
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the last day where three consecutive tests had p > 0.05.
Results
Six hundred and thirty-four participants were included
in the trial at randomisation (316 active and 318 pla-
cebo). Five hundred forty-six participants completed the
first season of the trial. When the trial was extended to
further four years, 351 participants continued in the ex-
tension (189 active, 162 placebo). These participants
were a representative subset of the population originally
included in the trial [12]. Two hundred and thirty-eight
participants (135 active, 103 placebo) completed the
planned five-year trial duration. There were 17,599 weekly
observations of EQ-5D, DSS and DMS used in model
development and 137,792 daily observations used in the
EQ-5D simulations. The baseline characteristics were
similar between the treatment groups and they have been
reported previously [13].
Binomial modelling
After variable selection, the final model utilised gender,
symptom score and medication score as fixed effects,
and subject and year of treatment as random effects to
predict ‘perfect’ health. Predictors that were considered
but deemed as contributing too little to the model and
thus omitted from the final model included age, treat-
ment arm, diagnosis of asthma, combined symptom/
medication score, the number of days with severe symp-
toms and study country. A summary of the first-stage,
mixed effects logistic model developed using weekly
diary data is provided in Table 1. Symptom score, followed
by medication score were the most ‘significant’ predictors
of ‘perfect’ health, reflecting a decrease in odds of ‘perfect’
health of 27% and 16% for each unit increase in score for
DSS and DMS, respectively (odds ratios of 0.7286 and
0.8406). There was also a small but significant interaction
effect (odds ratio of 1.0119) between DSS and DMS. Gen-
der was a ‘significant’ predictor, being male increased the
odds of ‘perfect’ health by 82% (odds ratio of 1.8169).
Comparing the predicted probabilities with observed pro-
portions yielded a NMSE of 0.39673, suggesting accept-
able model performance.Table 1 Summary of mixed effects logistic model (stage 1)
Fixed effects Estimate Std.
error
z value Pr (>|z|) Odds
ratio
(Intercept) 3.84611 0.24695 15.57 < 2e-16 -
Sex (male vs. female) 0.59713 0.24315 2.46 0.01406 1.8169
Symptom score -0.31662 0.02505 -12.64 < 2e-16 0.7286
Medication score -0.17369 0.03039 -5.72 1.1e-08 0.8406
Interaction (symptoms
and medication)
0.01185 0.00309 3.84 0.00013 1.0119By jointly optimising sensitivity and specificity, a
threshold probability of 0.960 was calculated. Using the
threshold and predicted probabilities from the first stage
(binomial) model; weekly observations were classified as
either ‘perfect health’ or ‘imperfect health’.
Continuous modelling
Weekly observations classified as ‘imperfect health’ were
used in the development of the second-stage generalized
linear mixed model summarised in Table 2. After vari-
able selection, the fixed effects of symptom and medica-
tion score and a subject random effect were sufficient to
predict the EQ-5D index in subjects identified as ‘imper-
fect’ health in the previous (binomial) modelling stage.
Predictors that were considered, but deemed as contrib-
uting too little to the model and thus omitted from the
final model, included gender, age, treatment arm, diag-
nosis of asthma, combined symptom/medication score,
the number of days with severe symptoms, year of treat-
ment and study country. A DSS and DMS interaction
term was tested but did not contribute ‘significantly’ to
the model and was therefore omitted. A unit increase in
symptom and medication score were associated with a
decrease of predicted EQ-5D summary score of 0.17 and
0.13, respectively.
Daily EQ-5D index simulation
Table 3 reports mean absolute error (MAE), mean squared
error (MSE) and root mean squared error (RMSE) of pre-
dicted compared to actual utility scores by EQ-5D utility
range for the two-part model using the weekly diary data.
Table 3 also reports mean observed and mean predicted
values to give an indication of over- or under-prediction,
whilst presenting means in this way can be misleading, the
pros outweigh the cons in this instance. MAE and MSE re-
ported in Table 3 suggest that the model predicts well over-
all and for the milder health states, but over predicts the
value for more severe health states. This poorer perform-
ance in the more severe states may be associated with the
distributions of actual EQ-5D utility values in Figure 1,
where there are relatively very few weekly observations in
the more severe health states. There are currently no
guidelines as to when estimation errors are and are not ac-
ceptable, but a systematic review of mapping studies [25]
has reported MAEs from 0.0011 to 0.19, and RMSEs fromTable 2 Summary of generalized linear mixed model
(stage 2)
Fixed effects Estimate Std. error t value Estimate
(original scale)
(Intercept) 0.516469 0.007012 73.7 0.8023
Symptoms score -0.004478 0.001053 -4.3 -0.1648
Medication score -0.001986 0.000891 -2.2 -0.1257
Table 3 Mean absolute error, mean squared error and root mean squared error of predicted compared to actual utility
scores by EQ-5D utility range using the weekly diary data
EQ-5D utility score Mean absolute
error
Mean squared
error
Root mean
squared error
Observed
mean
Predicted
mean
N (%)
<0.5 0.723 0.570 0.755 0.117 0.841 161 (0.92%)
0.5-0.599 0.275 0.086 0.293 0.561 0.836 78 (0.44%)
0.6-0.699 0.151 0.031 0.176 0.670 0.820 497 (2.82%)
0.7-0.799 0.085 0.017 0.130 0.749 0.834 684 (3.89%)
0.8-0.899 0.088 0.012 0.111 0.830 0.855 1542 (8.76%)
0.9-1.0 0.061 0.013 0.114 1.000 0.939 14637 (83.17%)
Full Index 0.074 0.019 0.138 0.956 0.923 17599 (100%)
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was outside of this range for the relatively severe health
states (EQ-5D < 6.0) where there were very few observations
(Figure 1), however overall MAE the model was 0.073.
The two-part model developed from the weekly diary
data was then applied to the daily diary data. Using the
first-stage model and associated threshold, 87,725 (63.7%)
of the 137,792 observations in the daily data were classi-
fied as ‘perfect health’ and assigned an EQ-5D summary
score of 1.000. The second-stage model was then applied
to the 50,067 (36.3%) daily observations that were classi-
fied as ‘imperfect health’ from the daily data, assigning
them a pseudo continuous EQ-5D index score. Where the
probability of ‘perfect health’ was less than the cut-off, the
continuous model was used to simulate the degree of ‘im-
perfect health’ for that data point.
Incremental QALYs
There was temporal and geographical variability in the
start dates and durations of grass pollen seasons between
sites and between years. The earliest and latest starts ofFigure 1 Histogram for weekly observed EQ-5D utility scores (TTO).grass pollen seasons were 4th April and 14thJune, re-
spectively. The earliest and latest ends of grass pollen
season were 7th June and 27th August, respectively. The
duration of the grass pollen seasons ranged from 15 to
116 days across all sites and all years. For this reason,
the mean utility value is presented by relative day of a
particular grass pollen season rather than by calendar
date. The mean EQ-5D index (with 95% CI) for the five-
year, pooled day of the pollen season, stratified by treat-
ment arm is given in Figure 2. The onset of incremental
utility benefit of GRAZAX® over placebo occurred at day
minus 30 of the pollen season and continued until day
+70. Between these dates the mean daily utility for GRA-
ZAX® patients was 0.938 units (95% CI 0.932 to 0.943)
compared with an average of 0.914 (95% CI 0.907 to
0.921) for placebo, an incremental difference of 0.0238
units (p < 0.001).
Figure 3 shows improvement in the mean predicted
EQ-5D for GRAZAX® and placebo subjects across the
spectrum of pollen count days. The area between the
curves during the 100-day benefit period defined above
Figure 2 Primary axis: predicted pooled mean daily utility for study period, stratified by treatment arm (GRAZAX®, red line; placebo,
green line [with 95% CI]). Secondary axis: proportion of study sample with observations by day of pollen season (GRAZAX®, red bars; placebo,
green bars).
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Adjusted Life Years (QALYs), or 0.0324 QALYs over the
five year study period.
Discussion
It was possible to determine an overall difference in
health-related utility between those treated with GRA-
ZAX® and those treated with placebo.Figure 3 Predicted daily utility by pollen count, stratified by treatmen
95% CIs).This study is the most comprehensive formal investiga-
tion of the relationship between health-related utility and
allergic rhinoconjunctivitis symptom severity. Use of a
two-part modelling approach reduced the adverse impact
of the highly skewed multimodal distribution of EQ-5D
index, especially in a population of relatively young adults
with low co-morbidity, among whom the majority of EQ-
5D health states indicated ‘perfect’ health. The adjustedt arm (GRAZAX®, red: placebo, green; dotted lines represent
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approach recently proposed by Hernández et al. [26] pro-
vides a credible alternative to the two-part modelling
approach used in the current study. Unfortunately
Hernández et al. did not compare their approach with
‘two part’ modelling, therefore we opted for the latter
which has been shown to perform consistently better than
censored regression. It is important to note that the
current study is not a comparative assessment of statistical
methodology, and the adoption of ALDVMM would have
been non-trivial to due to some of issues with estimation
of mixture models, such as local optima. Until there are
libraries and/or functionality in the mainstream statistical
packages these methods will be out of reach for many
researchers. Despite a modest sample size, the use of re-
peated measures mixed modelling ensured efficient use of
the repeated observations. Our results showed unequivo-
cally that the strongest predictors of the EQ-5D index ―
health-related utility ― in this population were rhinocon-
junctivitis symptom score followed by medication score.
Although variable length of pollen season from year-
to-year could confound the observed QoL benefits, the
presentation of a five-year ‘average’ pollen season would
mitigate this, and for the purposes of health economic
evaluation an ‘average’ pollen season is a reasonable con-
struct. This would be confounded if some systematic
change in the length of pollen seasons had been evident
during the study, however this was not the case.
The five-year, pooled incremental simulated utility was
strikingly similar to the reported increment of 0.0287
units taken from the first year’s data in the same trial
[27], supporting the assumption of maintained QALY
gain for GRAZAX® used in cost-effectiveness modelling
with a longer time horizon than the initial treatment
phase. Our findings confirm that the beneficial impact of
GRAZAX® on health-related utility seen in the first year
of treatment was carried forward through all five years
observed here. Interestingly, the pattern of pooled data
also seemed to indicate a pre-season utility benefit for
patients receiving GRAZAX® compared to patients re-
ceiving placebo. This is reasonable given that the defin-
ition of a pollen season for the purposes of the study
would not preclude ‘out-of-season’ individual days with
a high pollen count. However, the correlation of EQ-5D
to the rhinoconjunctivitis symptom and medication
scores was determined for the scales used in the GRA-
ZAX trials, meaning that a separate correlation has to
be evaluated for trials using other symptom and medica-
tion scorings. The original hypothesis for this study was
that weekly measurement of EQ-5D may not fully
capture the disutility associated with a disease which has
a highly variable symptom course that varies daily ac-
cording to meteorological variation and therefore might
underestimate the benefit of primary prevention treatment.Having conducted the experiment using justifiable model-
ling methods, we were unable to refute the null hypothesis.
Some commentators might observe that the incremental
utility seen in this study was lower than the lowest esti-
mate of the minimum clinically important difference
(MCID) for the EQ-5D index (0.033) [28]. This would in
fact create a misleading picture of the quality of life bene-
fits of GRAZAX® experienced by patients as the relative
insensitivity of EQ-5D to changes in rhinoconjunctivitis
symptom severity is documented. In a comparison of pa-
tients with seasonal allergic conjunctivitis and matched
controls, Pitt et al. [4] found that despite significant differ-
ences (p < 0.001) in all domains of the Rhinoconjunctivitis
Quality of Life Questionnaire, only the pain/discomfort
domain of the EQ-5D differed modestly in these patients.
A repeat of the same study design in Spain reported simi-
lar effect sizes [29].
The relative insensitivity of the EQ-5D to rhinocon-
junctivitis symptom severity is perhaps to be expected.
The EQ-5D does not record impairment in important
QoL domains adverse affected by rhinoconjunctivitis
symptoms such as sleep quality and workplace product-
ivity. The Spanish study (mainly moderate-severe symp-
toms) found that over half of the subjects experienced
poor sleep quality, while one-fifth suffered excessive di-
urnal somnolence [30]. A systematic review of studies
comparing rhinoconjunctivitis symptoms with HRQoL
impairment found that sleep, daily activities, physical
and mental status and social functioning were all im-
pacted consistently [31]. Within the current study popu-
lation the relative difference in sleep problems between
GRAZAX® and placebo (Δ35%; p = 0.0009) was the high-
est of any domain of the Rhinoconjunctivitis Quality of
Life questionnaire (RQLQ) [14].
In addition, it has been demonstrated that conditions
(including AR) with lower symptom severity exhibit ceil-
ing effects which limits the discriminant ability of EQ-
5D [32]. Stull et al recommend inclusion of another util-
ity measure that can capture the lower-end of symptom
severity spectrum as a useful strategy for establishing
health utility in these patients. The Short Form 36-item
(SF-36) generic QoL questionnaire has been shown to
have acceptable discriminative properties in rhinocon-
junctivitis [33], suggesting that its associated utility index
the SF-6D might be a better choice of utility instrument
for this disease group. This finding is supported by a
longitudinal survey of young adults with seasonal rhino-
conjunctivitis in which significant differences in the fol-
lowing SF-36 domains were observed between baseline
outside the pollen season and peak season observations:
physical functioning, physical role, bodily pain and vital-
ity [34]. Vitality has been recognised to be a unique con-
tributor to SF-6D in certain clinical situations [35]. In
their review of the statistical properties of five different
Poole et al. Health and Quality of Life Outcomes 2014, 12:99 Page 8 of 9
http://www.hqlo.com/content/12/1/99utility instruments (including the EQ-5D), Palta et al.
found the SF-6D to be least prone to ceiling effects, and
showed least variation in responsiveness across the range
of values [36].
Conclusion
Rhinoconjunctivitis symptoms and associated medication
use are the main predictors of EQ-5D index utility in an
adult population with seasonal grass pollen-induced rhi-
noconjunctivitis. We have demonstrated that use of grass
allergen immunotherapy tablet 75,000 SQ-T exhibits long-
term QoL benefits over placebo.
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